You are here

China

Flow of US biotech VC dollars on track to match record 2018 levels — China? Not so much

Flow of US biotech VC dollars on track to match record 2018 levels — China? Not so much

Endpoints

venture capital

Flag link:

Merck’s KEYTRUDA approved as monotherapy in China for first-line treatment of certain patients with advanced NSCLC

Merck’s KEYTRUDA approved as monotherapy in China for first-line treatment of certain patients with advanced NSCLC

Pharmaceutical Business Review

non-small cell lung cancer

Flag link:

Could the U.S.-China trade war stifle medical device innovation?

Could the U.S.-China trade war stifle medical device innovation?

Mass Device

Flag link:

Sanofi, AZ, Lilly and more win business in China's expanded cut-price purchase program

Sanofi, AZ, Lilly and more win business in China's expanded cut-price purchase program

Fierce Pharma

Flag link:

Couple stole trade secrets from U.S. children’s hospital to market their Chinese biotech, prosecutors say

Couple stole trade secrets from U.S. children’s hospital to market their Chinese biotech, prosecutors say

Stat

Flag link:

AZ gets China nod for Tagrisso in first-line lung cancer

AZ gets China nod for Tagrisso in first-line lung cancer

Pharmaforum

non-small cell lung cancer

Flag link:

China expands drug bulk-buy program, puts pressure on pharma firms

China expands drug bulk-buy program, puts pressure on pharma firms

Yahoo/Reuters

Flag link:

BeiGene's first U.S. NDA tests global development strategy

BeiGene's first U.S. NDA tests global development strategy

BioCentury

drug development

Flag link:

AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China

AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China

Yahoo/Zacks.com

chronic kidney disease

Flag link:

Biomedical stakeholders caution against limiting U.S.-China collaboration

Biomedical stakeholders caution against limiting U.S.-China collaboration

BioCentury

Flag link:

Is Pfizer's established drugs' decline in China the ‘canary in the coalmine?’

Is Pfizer's established drugs' decline in China the ‘canary in the coalmine?’

Fierce Pharma

Flag link:

China has become a CEO-level priority for multinational pharmaceutical companies: the trend and the implications

China has become a CEO-level priority for multinational pharmaceutical companies: the trend and the implications

Endpoints

pharma industry

Flag link:

These 7 trends matter the most for medtech in 2019

These 7 trends matter the most for medtech in 2019

Mass Device

robotic surgery

Intuitive Surgical

Flag link:

AstraZeneca raises sales forecast after second-quarter cancer drug, China boost

AstraZeneca raises sales forecast after second-quarter cancer drug, China boost

Yahoo/Reuters

Flag link:

Novartis multiple sclerosis product Gilenya approved in China

Novartis multiple sclerosis product Gilenya approved in China

Pharmaceutical Business Review

multiple sclerosis

Flag link:

HitGen joins growing Shanghai IPO queue

HitGen joins growing Shanghai IPO queue

BioCentury

Flag link:

Megadeals Enter Biotech Realm — And 3 Other Trends To Watch In 2019

Megadeals Enter Biotech Realm — And 3 Other Trends To Watch In 2019

Investors Business Daily

Flag link:

Trade tensions are impeding the flow of Chinese money to US biotechs — but how much?

Trade tensions are impeding the flow of Chinese money to US biotechs — but how much?

Endpoints

venture capital

Flag link:

Zai builds cancer combo strategy with rights to Incyte's PD-1 mAb

Zai builds cancer combo strategy with rights to Incyte's PD-1 mAb

BioCentury

PD-1 inhibitors

Flag link:

Another Biotech Plant Explosion in China Kills Six

Another Biotech Plant Explosion in China Kills Six

BioSpace

drug manufacturing

Flag link:

Pages